<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408446</url>
  </required_header>
  <id_info>
    <org_study_id>GZS01167261</org_study_id>
    <nct_id>NCT01408446</nct_id>
  </id_info>
  <brief_title>Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients</brief_title>
  <acronym>ESMAB</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of DANSHU Capsule(Menthol) and Placebo on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhiming Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prehypertension and mild hypertension are associated with an increased risk of
      atherosclerosis and coronary artery disease, and often complicated with the metabolic
      disorder of glucose and lipid. The comprehensive prevention of hypertension is still an
      important and complex clinical issue. Peppermint is a popular flavoring agent, and peppermint
      tea help relax tension and could lower blood pressure. The effect of oral peppermint on blood
      pressure is not consistent, however, our previous animal study has shown that oral
      administration of menthol, the main component of peppermint, could reduce 24-hour mean
      arterial systolic and diastolic blood pressure in spontaneous hypertensive rats. Furthermore,
      menthol increases uncoupling protein(UCP)1 dependent thermogenesis and energy expenditure
      through transient receptor potential melastatin(TRPM)8 activation, and helps prevent obesity
      and metabolic disorders. In a prospective, double-blind, randomized, and parallel-group
      study, we will evaluate the effects of DANSHU capsule(menthol) on blood pressure and
      metabolic parameters in prehypertensive and mild hypertensive patients. This study will help
      develop future comprehensive prevention and treatment strategies for hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decrease in diastolic blood pressure after an 8-week oral menthol administration</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluate the effects of DANSHU capsule(menthol) on blood pressure and metabolic parameters in prehypertensive and mild hypertensive patients after an 8-week oral administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypertension</condition>
  <condition>Prehypertension</condition>
  <arm_group>
    <arm_group_label>Menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions Drug: Menthol Arms: Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interventions Drug: Placebo Arms: Group 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menthol</intervention_name>
    <description>Capsule 48mg three times a day after meals 8 weeks</description>
    <arm_group_label>Menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule 48mg three times a day after meals 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood pressure: 120mmHg≤SBP&lt;160mmHg, and/or 80mmHg≤DBP&lt;100mmHg

        Exclusion Criteria:

          -  Diabetes

          -  Hypertension: SBP≥160mmHg, or DBP≥100mmHg

          -  known allergy to trial drugs

          -  Myocardial infarction or cerebrovascular accident in the year preceding the trial

          -  Clinical Congestive Heart Failure

          -  Secondary hypertension

          -  Pregnancy or lactating women

          -  Malignant tumor

          -  Gastroesophageal reflux or gastroduodenal ulcer

          -  History of hepatitis or cirrhosis

          -  History of kidney disease

          -  Body weight﹤35Kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongbo He, MD</last_name>
    <phone>86-023-68715705</phone>
    <email>cqhehongbo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongbo He, M.D.</last_name>
      <phone>86-23-68715705</phone>
      <email>qhehongbo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>October 27, 2013</last_update_submitted>
  <last_update_submitted_qc>October 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhiming Zhu</investigator_full_name>
    <investigator_title>Chief Scientist of the National Key Basic Research and Development Program (973 Program)</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Menthol</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

